Navigation Links
Completely novel action of insulin unveiled
Date:11/5/2008

A PhD student at Sydney's Garvan Institute of Medical Research has uncovered an important piece in the puzzle of how insulin works, a problem that has plagued researchers for more than 50 years. This finding brings us one step closer to explaining exactly how insulin prompts fat and muscle cells to absorb glucose.

The novel finding by Freddy Yip was published online today in the prestigious international journal, Cell Metabolism.

"Since the 1920s, when Banting and Best discovered insulin, scientists have been battling to discover how it actually works," said Professor David James, head of Garvan's Diabetes Program.

"Then along comes Freddy Yip, doing his PhD, who unveils a completely novel action of insulin, one which we believe plays a fundamental role in glucose uptake, a process that is defective in Type 2 diabetes."

There are two processes involved in Type 2 diabetes: insufficient production of insulin in the pancreas after a meal and faulty uptake and storage of glucose in fat and muscle cells, or 'insulin resistance'.

Freddy's finding focuses on the intersection between these two processes. "In the cell we have series of motor proteins that have the ability to move other molecules from one place to another along intracellular rail road tracks," he explained.

"I have discovered that insulin activates a specific kind of motor protein known as Myo1c, which in turn performs a critical role in glucose uptake."

Insulin controls glucose uptake into our fat cells by moving glucose transporter proteins from inside the cell to the surface membrane so that they can pump glucose into the cell. Myo1c aids in this process by helping the transporters slide into the surface membrane.

In healthy people, around 80% of the glucose transporters migrate to the cell membrane after a meal, allowing plenty of glucose into the cell. In people with Type 2 diabetes, however, that figure drops to around 10%.

Freddy Yip believes his study will create a strong foundation for future diabetes research. "We knew before that Myo1c was somehow involved in the regulation of glucose transport. My research indicates that Myo1c is a major target of insulin action and helps to accelerate the delivery of transporters to the membrane," he said.

"We think there may be blockages in the signal between insulin and myo1c in people who develop insulin resistance. If we're correct, it should be possible to target that pathway for development of new therapies."

Professor James sees the finding as a welcome milestone on a very long road of discovery. "While we're certainly not saying we've found a way to cure diabetes, we are saying we've found a pretty significant clue."


'/>"/>

Contact: Alison Heather
a.heather@garvan.org.au
61-434-071-326
Research Australia
Source:Eurekalert

Related medicine news :

1. World first: researchers develop completely automated anesthesia system
2. Yo Mujer: Woman Escapes from Abusive Marriage in New Spanish-Language Novel
3. Moores UCSD Cancer Center studying novel leukemia vaccine for high-risk patients
4. Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrate Superior Profile of S*BIOs Novel Anti-Cancer Drug SB939
5. Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications
6. NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting
7. Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center
8. Novel imaging approach may assist in predicting success of treatment for atrial fibrillation
9. NIH Awards a Phase I Small Business Innovative Research Grant on "Novel Laser Scanning Technology for Computed Radiography" to VIXAR and iCRco
10. Novel tuberculosis vaccine in Germany in clinical phase
11. VCU Massey Cancer Center spearheads novel clinical study for lymphoma patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... , ... August 18, 2017 , ... ... aimed at creating a transparent, verifiable database to help the cannabis industry move ... technology, Paragon hopes to deliver a faster technology with lower fees. Paragon will ...
(Date:8/19/2017)... , ... August 19, 2017 , ... ... contemporary illustrations of breastfeeding mothers. These illustrations show the diversity of the ... prints in a wide range of sizes. These illustrations are also available on ...
(Date:8/19/2017)... ... August 19, 2017 , ... “Congratulations! It's A Boy! God’s Gift: ... both their parents and God. “Congratulations! It's A Boy! God’s Gift: A Story of ... from Long Island, New York. , Published by Christian Faith Publishing, Dale Anthony and ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions for ... agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation Systems, ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an industry leader, Eppendorf ... they will present the line of epMotion automated liquid handling system. This automated ... automate everyday pipetting tasks. , Ideal for scientists and lab technicians with no ...
Breaking Medicine News(10 mins):
(Date:8/10/2017)... , Aug. 10, 2017  Physical Rehabilitation Network (PRN), ... in Lakewood, Colorado . The reputable clinic ... Lipkin , PT, DPT with his staff of four clinicians. ... of Pittsburgh and brings over 10 years of experience with ... Belmar PT marks the 10th PRN clinic in and ...
(Date:8/7/2017)... GAITHERSBURG, Md. , Aug. 7, 2017 /PRNewswire/ ... for healthcare member acquisition, retention, and engagement, announced ... Director of Strategy and Product Development, effective as ... strategic consulting and technology implementation strategy for our ... years of experience in consulting and business analytics ...
(Date:8/7/2017)... Mich., Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), ... the quarter ended June 30, 2017.  All comparisons, unless otherwise ... Second Quarter 2017 Highlights ... to $1,089 million, an increase of 3.5% ... Gross margin of 7.5% versus 7.6% ...
Breaking Medicine Technology: